Vyxeos
Term · Oncology and biomedicine · MLC-T-ONC-009331
A form of the anticancer drugs daunorubicin hydrochloride and cytarabine that is contained inside very tiny, fat-like particles and is used to treat adults with certain types of newly diagnosed acute myeloid leukemia. Vyxeos may have fewer side effects and work better than other forms of these drugs. It is also being studied in the treatment of other types of cancer. Vyxeos is a type of anthracycline antibiotic, a type of topoisomerase inhibitor, and a type of antimetabolite. Also called daunorubicin hydrochloride and cytarabine liposome.
| Identifier | MLC-T-ONC-009331 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | daunorubicin hydrochloride and cytarabine liposome |
| References | NCI Dictionary of Cancer Terms |
Record as JSON
{
"id": "MLC-T-ONC-009331",
"term": "Vyxeos",
"field": "Oncology and biomedicine",
"definition": "A form of the anticancer drugs daunorubicin hydrochloride and cytarabine that is contained inside very tiny, fat-like particles and is used to treat adults with certain types of newly diagnosed acute myeloid leukemia. Vyxeos may have fewer side effects and work better than other forms of these drugs. It is also being studied in the treatment of other types of cancer. Vyxeos is a type of anthracycline antibiotic, a type of topoisomerase inhibitor, and a type of antimetabolite. Also called daunorubicin hydrochloride and cytarabine liposome.",
"synonyms": [
"daunorubicin hydrochloride and cytarabine liposome"
],
"references": [
"NCI Dictionary of Cancer Terms"
],
"url": "https://mlchart.com/terminology/oncology/vyxeos/"
}
Record 17,370 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.